Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

SML0506

Sigma-Aldrich

LY-411575

≥97% (HPLC)

Sinonimo/i:

LSN-411575, LY 411575, N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C26H23F2N3O4
Numero CAS:
209984-57-6
Peso molecolare:
479.48
Numero MDL:
MFCD09832551
Codice UNSPSC:
12352200
ID PubChem:
329825453
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥97% (HPLC)

Forma fisica

powder

Colore

white to beige

Solubilità

DMSO: 5 mg/mL, clear

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Stringa SMILE

C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@@H]2C(=O)N(C)c3ccccc3-c4ccccc24

InChI

1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1
ULSSJYNJIZWPSB-CVRXJBIPSA-N

Applicazioni

LY-411575 has been used as a potent γ-secretase inhibitor and Notch inhibitor.

Azioni biochim/fisiol

LY-411575 is potent, cell permeable and selective γ-secretase inhibitor that reduces Aβ/42 after acute or chronic treatment, and blocks Notch activation. Studies (Cancer Cell) have shown that treatment with LSN-411575 arrests KrasG12V-driven NSCLCs in association with inhibition of HES1 expression and ERK phosphorylation.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

γ-Secretase Inhibitor I The γ-Secretase Inhibitor I controls the biological activity of γ-Secretase. This small molecule/inhibitor is primarily used for Neuroscience applications.

Sigma-Aldrich

565750

γ-Secretase Inhibitor I

γ-Secretase Inhibitor IX InSolution, ≥95%, 25 mM, g-secretase Inhibitor IX

Millipore

565784-M

γ-Secretase Inhibitor IX

γ-Secretase Inhibitor IX Gamma-Secretase Inhibitor IX - CAS 208255-80-5, is a cell-permeable inhibitor of γ-secretase (Aβtotal IC₅₀ = 115 nM, Aβ42 IC₅₀ = 200 nM).

Sigma-Aldrich

565770

γ-Secretase Inhibitor IX

LY2090314 ≥98% (HPLC)

Sigma-Aldrich

SML1438

LY2090314

Nifuroxazide VETRANAL®, analytical standard

Supelco

46494

Nifuroxazide

CHIR99021 ≥98% (HPLC)

Sigma-Aldrich

SML1046

CHIR99021

2-Phospho-L-ascorbic acid trisodium salt ≥95.0% (HPLC)

Sigma-Aldrich

49752

2-Phospho-L-ascorbic acid trisodium salt

Prion-protein-interacting amyloid-β oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models.
Kostylev M A, et al.
The Journal of Biological Chemistry, 290(28), 17415-17438 (2015)
Enzymatic assays for studying intramembrane proteolysis.
Bolduc D M, et al.
Methods in Enzymology, 584, 295-308 (2017)
Different developmental histories of beta-cells generate functional and proliferative heterogeneity during islet growth.
Singh S P, et al.
Nature Communications, 8(1), 664-664 (2017)
K Pandya et al.
British journal of cancer, 105(6), 796-806 (2011-08-19)
We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both
Kyung-Won Park et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(7), 2294-2307 (2021-03-02)
Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.